Resumo

MONTANO-FIGUEROA, Efreen H.  e  GOMEZ-ALMAGUER, David. Aplastic anemia. Gac. Méd. Méx [online]. 2021, vol.157, suppl.3, pp.S52-S54.  Epub 25-Abr-2022. ISSN 2696-1288.  https://doi.org/10.24875/gmm.m21000472.

Medical practice in general has changed due to coronavirus disease 2019 (COVID-19) pandemic. Some hematologic diseases require immunosuppresive therapy placing patients at high risk of infection, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Aplastic anemia (AA) especially the very severe type in which the count of absolute neutrophils is less than 200/ml is a life-threatening condition. Although bone marrow transplant is a potential curative treatment, it should be delayed temporally in order to prevent a contagion. Hospitalization may expose patients to infection, thus an ambulatory immunosuppression with oral cyclosporine and thrombopoietin agonist should be an adequate option. This work reviews international and national treatment recommendations and follow-up of patients with AA based on experiences from countries that have already faced this health emergency.

Palavras-chave : Aplastic anemia; Immunosuppressive therapy; Eltrombopag; COVID-19.